Find the latest covid-19 vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valneva, a European ...

The global pandemic caused due to Covid-19 has come into focus again with the aspect of the vaccine's ability to be effective against the deadly disease. Elon Musk comments on X (formerly known as ...

Since pharmaceutical companies Pfizer and Valneva announced positive results from their phase 3 trial of a vaccine to prevent Lyme disease last month, two questions have loomed large: Will the vaccine ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

Pfizer and BioNTech have halted a U.S. study of their updated COVID-19 vaccine in adults ages 50-64 due to slow enrollment, a Pfizer spokesperson confirmed to Becker’s. “We can confirm our ...

Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

Poland and Romania have been ordered by a Belgian court to pay Pfizer Inc. €1.9 billion ($2.2 billion) for Covid-19 vaccines the two countries refused to take delivery of during the pandemic, handing ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the ...